<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141232</url>
  </required_header>
  <id_info>
    <org_study_id>A2581114</org_study_id>
    <nct_id>NCT00141232</nct_id>
  </id_info>
  <brief_title>Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes</brief_title>
  <acronym>AFORRD</acronym>
  <official_title>A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Churchill Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The AFORRD trial is asking three important questions:

      What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a
      fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart
      disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given
      with or without a statin? Are there simple techniques that can help people to take their
      tablets on a regular basis?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prim objective (16 wks) for atorvastatin: Proportion of pats. who achieve measured</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL levels &lt;2.6 mmol/L (&lt;100 mg/dl) Prim object (16 wks) for Omega-3 fatty acid:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prop of pats. who achieve measured triglycerides &lt;1.5 mmol/L (&lt;200 mg/dl)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prop of pats who achieve LDL levels &lt;2.6 mmol/L (&lt;100 mg/dl) at 52 weeks, taking into account whether the patient received additional atorvastatin therapy or placebo at week 16.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prop of pats who achieve triglycerides &lt;1.5 mmol/L (&lt;200 mg/dl) at 52 weeks.</measure>
  </secondary_outcome>
  <enrollment type="Actual">810</enrollment>
  <condition>Diabetes, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin and Omega-3 fatty acids</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to
             entry.

          -  Are not known to have had a cardiovascular event

        Exclusion Criteria:

          -  They are taking prescribed lipid lowering therapy

          -  Have triglycerides &gt; or = 8.0 mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>Ayrshire</state>
        <zip>KA12 OAY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Farnworth</city>
        <state>Bolton</state>
        <zip>BL4 9AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <state>Cardiff</state>
        <zip>CF14 9BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Launceston</city>
        <state>Cornwall</state>
        <zip>PL15 9HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Penzance</city>
        <state>Cornwall</state>
        <zip>TR18 4JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Penzance</city>
        <state>Cornwall</state>
        <zip>TR19 7HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saltash</city>
        <state>Cornwall</state>
        <zip>PL12 6DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St Austell</city>
        <state>Cornwall</state>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Darlington</city>
        <state>County Durham</state>
        <zip>DL16 6QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newton Aycliffe</city>
        <state>County Durham</state>
        <zip>DL5 5NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Three Bridges</city>
        <state>Crawley</state>
        <zip>RH10 1LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 7TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bexhill on Sea</city>
        <state>East Sussex</state>
        <zip>TN39 4SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bexhill-On-Sea</city>
        <state>East Sussex</state>
        <zip>TN40 2SD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bath</city>
        <state>England</state>
        <zip>BA2 4JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dronfield, Sheffield</city>
        <state>England</state>
        <zip>S18 1RU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>England</state>
        <zip>CR7 7JN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halstead</city>
        <state>Essex</state>
        <zip>CO9 1EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stonehouse</city>
        <state>Gloucestershire</state>
        <zip>GL10 2NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO31 7DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hildenborough</city>
        <state>Kent</state>
        <zip>TN11 9HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thorneton-Clevely</city>
        <state>Lancashire</state>
        <zip>FY5 3LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Balham</city>
        <state>London</state>
        <zip>SW12 8EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fulham</city>
        <state>London</state>
        <zip>SW6 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 9SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hayes</city>
        <state>Middlesex</state>
        <zip>UB4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wellingborough</city>
        <state>Northamptonshire</state>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cookstown</city>
        <state>Northern Ireland</state>
        <zip>BT80 8BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frome</city>
        <state>Somerset</state>
        <zip>BA11 1EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fetcham</city>
        <state>Surrey</state>
        <zip>KT22 9LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woking</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Crawley</city>
        <state>West Sussex</state>
        <zip>RH10 7DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS12 1JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bradford-on-Avon</city>
        <state>Wiltshire</state>
        <zip>BA1 5DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melksham</city>
        <state>Wiltshire</state>
        <zip>SN12 6UN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <zip>SN25 4YZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <state>Wiltshire</state>
        <zip>BA14 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warminster</city>
        <state>Wiltshire</state>
        <zip>BA12 9AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S7 2DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 1NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT4 1NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B37 7TR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucks</city>
        <zip>HP22 5LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chippenham, Wiltshire</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cornwall</city>
        <zip>TR18 2RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>County Antrim, Northern Ireland</city>
        <zip>BT41 3AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Darlington</city>
        <zip>DL3 6HZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD2 5NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD4 6QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>East Sussex</city>
        <zip>TN40 3RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Isle of Wight</city>
        <zip>PO32 6RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Isle of Wight</city>
        <zip>PO33 2PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>N19 5EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW19 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Westbury</city>
        <zip>BA13 3JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581114&amp;StudyName=Evaluating+Atorvastatin+with+Omega%2D3+Fatty+Acids+in+Cardiovascular+Risk+Reduction+in+Patients+with+Type+2+Diabetes</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>November 21, 2008</last_update_submitted>
  <last_update_submitted_qc>November 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

